A Mass Balance Study of [14C] SHR6508 in Chinese Hemodialysis Subjects With Secondary Hyperparathyroidism
Latest Information Update: 26 Mar 2026
At a glance
- Drugs SHR 6508 (Primary)
- Indications Secondary hyperparathyroidism
- Focus Pharmacokinetics
- Sponsors Shanghai Hengrui Pharmaceutical
Most Recent Events
- 23 Mar 2026 Status changed from active, no longer recruiting to completed.
- 17 Apr 2025 Status changed from recruiting to active, no longer recruiting.
- 19 Mar 2025 New trial record